The features of the newly emerging SARS-CoV-2 Omicron BA.2.75 subvariant
Can't see this email? View it online
   
  COVID-19  
  The latest COVID-19 news from News Medical  
 The features of the newly emerging SARS-CoV-2 Omicron BA.2.75 subvariantThe features of the newly emerging SARS-CoV-2 Omicron BA.2.75 subvariant
 
Researchers evaluated all the features, especially the antigenic properties and transmission potential of SARS-CoV-2 Omicron sub-variant BA.2.75.
 
 
 Double mRNA COVID-19 vaccination found to increase SARS-CoV-2 variant recognitionDouble mRNA COVID-19 vaccination found to increase SARS-CoV-2 variant recognition
 
Researchers evaluated the impact of double BNT162b2 messenger ribonucleic acid (mRNA) vaccination in recognition of SARS-CoV-2 variants of concern.
 
   Study identifies broad-spectrum antibody that neutralizes SARS-CoV-2 variants of concernStudy identifies broad-spectrum antibody that neutralizes SARS-CoV-2 variants of concern
 
Scientists have described the identification and therapeutic evaluation of an antibody that broadly neutralizes major variants of SARS-CoV-2, including the alpha, beta, delta, and omicron variants.
 
   Study finds COVID associated with abnormal placental pathologies in nearly 50% of cohortStudy finds COVID associated with abnormal placental pathologies in nearly 50% of cohort
 
Researchers describe the impact of placental morphological changes in COVID-19 on pregnancy outcomes.
 
   Study suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariantsStudy suggests BA.5 evolved to induce enhanced inflammation when compared to prior Omicron subvariants
 
Researchers evaluated the comparative pathogenicity of SARS-CoV-2 Omicron sub-variants BA.1, BA.2, and BA.5, in vitro and in vivo.
 
 French study on cardiovascular disease incidence during COVID pandemic and vaccination campaign
 
French study on cardiovascular disease incidence during COVID pandemic and vaccination campaignResearchers describe failures of the French healthcare system as reflected by increased hospitalizations due to certain acute cardiovascular diseases in 2021.
 
 
 Fatigue and headache among the most common symptoms following COVID-19 infections
 
Fatigue and headache among the most common symptoms following COVID-19 infectionsFatigue and headache were the most common symptoms reported by individuals an average of more than four months out from having COVID-19, investigators report.
 
 
 Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19
 
Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19A recent paper describes the use of aprotinin, a protease inhibitor that works across several pathways, to reduce the severity of COVID-19.
 
 
 Gut microbiota-derived metabolites offer protection against SARS-CoV-2
 
Gut microbiota-derived metabolites offer protection against SARS-CoV-2A new study investigated how the gut microbiome confers immunity to mammalian hosts against SARS-CoV-2 intranasal infection by generating short-chain fatty acids.
 
 
 Review of natural products with promising anti-SARS-CoV-2 potential
 
Review of natural products with promising anti-SARS-CoV-2 potentialIn a new study, researchers reviewed existing literature on naturally active products with therapeutic efficacy against SARS-CoV-2.
 
 
 The impact of cold agglutinin syndrome on clinical presentations in COVID-19
 
The impact of cold agglutinin syndrome on clinical presentations in COVID-19Researchers presented two cases to highlight the impact of cold agglutinin syndrome on clinical presentations in COVID-19.
 
 
 Experts analyze the nature, prevalence, and severity of long-term symptoms related to COVID-19
 
Experts analyze the nature, prevalence, and severity of long-term symptoms related to COVID-19One in eight adults (12.7%) who are infected with SARS-CoV-2 experience long term symptoms due to COVID-19, suggests a large Dutch study published in The Lancet.
 
 
 How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants?
 
How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants?Scientists analyzed the differences between SARS-CoV-2 rebound associated with the Omicron BA.2.12.1 and BA.5 sublineages post-Paxlovid therapy in the United States.
 
 
 Evaluating vaccine effectiveness against Omicron BA.5 and BA.2 in Portugal
 
Evaluating vaccine effectiveness against Omicron BA.5 and BA.2 in PortugalResearchers estimated the vaccine effectiveness (VE) of the primary and booster doses of COVID-19 vaccines against reinfection by Omicron BA.5 and BA.2 lineages and severe post-infection outcomes.
 
 
 MIT researchers develop an easy-to-use test to predict Covid-19 immunity
 
MIT researchers develop an easy-to-use test to predict Covid-19 immunityMost people in the United States have some degree of immune protection against Covid-19, either from vaccination, infection, or a combination of the two. But, just how much protection does any individual person have?
 
 
 Study tests equine polyclonal antibodies against SARS-CoV-2 variants
 
Study tests equine polyclonal antibodies against SARS-CoV-2 variantsA recent study published tested equine polyclonal antibodies against SARS-CoV-2.
 
 
 Post-COVID-19 symptoms may occur in one of eight SARS-CoV-2-infected individuals
 
Post-COVID-19 symptoms may occur in one of eight SARS-CoV-2-infected individualsIn a new study, researchers analyzed the nature, incidence, and severity of 23 COVID-19-related persistent symptoms in the Netherlands.
 
 
 BA.2.75: A new, highly virulent SARS-CoV-2 variant
 
BA.2.75: A new, highly virulent SARS-CoV-2 variantIn this article, ACROBiosystems discusses BA.2.75, a newly emerging SARS-CoV-2 variant with surprising transmission speed, and the potential ramifications this has against the ongoing fight against COVID-19.